|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Health Policy Raw citation data, Impact Factor, Immediacy Index, Published documents, Citations received, , Most cited papers , Recent citations and documents published in this series in EconPapers.
Most cited documents in this series: (1) RePEc:eee:hepoli:v:47:y:1999:i:2:p:97-123 The contingent valuation method in health care (1999). (2) RePEc:eee:hepoli:v:54:y:2000:i:2:p:87-123 Review of the literature on reference pricing (2000). (3) RePEc:eee:hepoli:v:37:y:1996:i:1:p:53-72 EuroQol: the current state of play (1996). (4) RePEc:eee:hepoli:v:24:y:1993:i:3:p:227-238 The trade-off between severity of illness and treatment effect in cost-value analysis of health care (1993). (5) RePEc:eee:hepoli:v:63:y:2003:i:1:p:17-36 The economic impact of malaria in Africa: a critical review of the evidence (2003). (6) RePEc:eee:hepoli:v:40:y:1997:i:3:p:237-255 Household income and health care expenditures in Mexico (1997). (7) RePEc:eee:hepoli:v:67:y:2004:i:2:p:149-165 Incentives and pharmaceutical reimbursement reforms in Spain (2004). (8) RePEc:eee:hepoli:v:49:y:1999:i:1-2:p:63-74 Public views on health care rationing: a group discussion study (1999). (9) RePEc:eee:hepoli:v:34:y:1995:i:2:p:135-143 Value for money? A contingent valuation study of the optimal size of the Swedish health care budget (1995). (10) RePEc:eee:hepoli:v:72:y:2005:i:2:p:201-215 Tackling excessive waiting times for elective surgery: a comparative analysis of policies in 12 OECD countries (2005). (11) RePEc:eee:hepoli:v:51:y:2000:i:1:p:19-30 A qualitative study of the extent to which health gain matters when choosing between groups of patients (2000). (12) RePEc:eee:hepoli:v:68:y:2004:i:2:p:197-209 The impact of urban health insurance reform on hospital charges: a case study from two cities in China (2004). (13) RePEc:eee:hepoli:v:65:y:2003:i:1:p:21-35 Needs for further improvement: risk adjustment in the German health insurance system (2003). (14) RePEc:eee:hepoli:v:17:y:1991:i:1:p:1-23 Economic evaluation in health care: Is there a role for cost-benefit analysis? (1991). (15) RePEc:eee:hepoli:v:57:y:2001:i:2:p:141-153 Scope and scale insensitivities in a contingent valuation study of risk reductions (2001). (16) RePEc:eee:hepoli:v:51:y:2000:i:2:p:109-131 An update on Spains health care system: is it time for managed competition? (2000). (17) RePEc:eee:hepoli:v:57:y:2001:i:1:p:1-13 Health economics in low income countries: adapting to the reality of the unofficial economy (2001). (18) RePEc:eee:hepoli:v:41:y:1997:i:1:p:1-36 Structured pluralism: towards an innovative model for health system reform in Latin America (1997). (19) RePEc:eee:hepoli:v:44:y:1998:i:3:p:233-252 Primary health care meets the market in China and Vietnam (1998). (20) RePEc:eee:hepoli:v:60:y:2002:i:3:p:201-218 Policy relevant determinants of health: an international perspective (2002). (21) RePEc:eee:hepoli:v:44:y:1998:i:2:p:123-134 Effects of user charges on the use of prescription medicines in different socio-economic groups (1998). (22) RePEc:eee:hepoli:v:69:y:2004:i:1:p:55-72 Technical efficiency in the use of health care resources: a comparison of OECD countries (2004). (23) RePEc:eee:hepoli:v:65:y:2003:i:2:p:167-179 The availability of drugs: what does it mean in Ugandan primary care (2003). (24) RePEc:eee:hepoli:v:55:y:2001:i:1:p:51-69 Health-related quality of life by disease and socio-economic group in the general population in Sweden (2001). (25) RePEc:eee:hepoli:v:60:y:2002:i:3:p:235-254 Free choice of sickness funds in regulated competition: evidence from Germany and The Netherlands (2002). (26) RePEc:eee:hepoli:v:68:y:2004:i:1:p:47-54 The effect of generic competition on the price of brand-name drugs (2004). (27) RePEc:eee:hepoli:v:38:y:1996:i:2:p:117-128 The costs of nursing turnover: evidence from the British National Health Service (1996). (28) RePEc:eee:hepoli:v:60:y:2002:i:2:p:133-150 Reforming Chinas urban health insurance system (2002). (29) RePEc:eee:hepoli:v:68:y:2004:i:1:p:113-121 The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation (2004). (30) RePEc:eee:hepoli:v:46:y:1998:i:1:p:21-41 The new pharmaceutical policy in Italy (1998). (31) RePEc:eee:hepoli:v:43:y:1998:i:2:p:171-194 The German health care system and health care reform (1998). (32) RePEc:eee:hepoli:v:52:y:2000:i:1:p:53-70 On hypothetical bias and calibration in cost-benefit studies (2000). (33) RePEc:eee:hepoli:v:58:y:2001:i:1:p:83-96 Policy implications of the inadequate support systems for orphans in Western Kenya (2001). (34) RePEc:eee:hepoli:v:40:y:1997:i:3:p:199-215 The role of economic evaluation in the pricing and reimbursement of medicines (1997). (35) RePEc:eee:hepoli:v:43:y:1998:i:1:p:33-44 Value measurement in cost-utility analysis: explaining the discrepancy between rating scale and person trade-off elicitations (1998). (36) RePEc:eee:hepoli:v:35:y:1996:i:3:p:205-216 An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy (1996). (37) RePEc:eee:hepoli:v:57:y:2001:i:2:p:111-139 The potential demand for an AIDS vaccine in Thailand (2001). (38) RePEc:eee:hepoli:v:28:y:1994:i:2:p:133-141 Cost-effectiveness ratios: in a league of their own (1994). (39) RePEc:eee:hepoli:v:72:y:2005:i:1:p:53-63 Pharmaceutical policy in Italy: towards a structural change? (2005). (40) RePEc:eee:hepoli:v:20:y:1992:i:3:p:309-320 Economic evaluation of lipid lowering -- A feasibility test of the contingent valuation approach (1992). (41) RePEc:eee:hepoli:v:42:y:1997:i:2:p:145-155 The importance of lifestyle to self-assessed health (1997). (42) RePEc:eee:hepoli:v:34:y:1995:i:2:p:145-151 The efficacy and equity of retransplantation: an experimental survey of public attitudes (1995). (43) RePEc:eee:hepoli:v:50:y:2000:i:3:p:197-218 Drug cost containment policies in Italy: are they really effective in the long-run?: The case of minimum reference price (2000). (44) RePEc:eee:hepoli:v:71:y:2005:i:2:p:213-222 Tobacco consumption patterns and its health implications in India (2005). (45) RePEc:eee:hepoli:v:66:y:2003:i:1:p:73-93 Service production and contract choice in primary physician services (2003). (46) RePEc:eee:hepoli:v:31:y:1995:i:2:p:103-110 The use of economic evaluation in health care: Australian decision makers perceptions (1995). (47) RePEc:eee:hepoli:v:43:y:1998:i:1:p:15-31 Income-based incentives in UK general practice (1998). (48) RePEc:eee:hepoli:v:21:y:1992:i:3:p:249-279 Cost-utility in practice: A policy makers guide to the state of the art (1992). (49) RePEc:eee:hepoli:v:28:y:1994:i:2:p:89-132 Cost containment and health care reform: a study of the European Union (1994). (50) RePEc:eee:hepoli:v:32:y:1995:i:1-3:p:125-139 Abnormal economics in the health sector (1995). Recent citations received in: | 2006 | 2005 | 2004 | 2003 Recent citations received in: 2006 (1) RePEc:lug:wpaper:0607 Small area variations and welfare loss in the use of antibiotics in the community (2006). Biblioteca universitaria di Lugano (University Library of Lugano) / Quaderni della facoltà di Scienze economiche dell'Università di Lugano Recent citations received in: 2005 (1) RePEc:fda:fdaddt:2005-15 Measuring Changes in Health Capital (2005). FEDEA / Working Papers (2) RePEc:ind:igiwpp:2005-003 Price elasticity estimates for tobacco and other addictive goods in India (2005). Indira Gandhi Institute of Development Research, Mumbai, India / Indira Gandhi Institute of Development Research, Mumbai Working Papers (3) RePEc:ssa:lemwps:2005/24 Innovation and Standards in Clinical Practice: The Case of HIV Treatments (2005). Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy / LEM Papers Series (4) RePEc:wly:hlthec:v:14:y:2005:i:s1:p:s187-s202 The Italian health-care system (2005). Health Economics Recent citations received in: 2004 (1) RePEc:upf:upfgen:762 Regulatory Ambivalence and the Limitations of Pharmaceutical Policy in Spain (2004). Department of Economics and Business, Universitat Pompeu Fabra / Economics Working Papers (2) RePEc:upf:upfses:762 Regulatory Ambivalence and the Limitations of Pharmaceutical Policy in Spain (2004). Department of Economics and Business, Universitat Pompeu Fabra / Working Papers, Research Center on Health and Economics Recent citations received in: 2003 Warning!! This is still an experimental service. The results of this service should be interpreted with care, especially in research assessment exercises. The processing of documents is automatic. There still are errors and omissions in the identification of references. We are working to improve the software to increase the accuracy of the results. Source data used to compute the impact factor of RePEc series. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
